News articles about Intellia Therapeutics (NASDAQ:NTLA) have trended somewhat positive on Thursday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Intellia Therapeutics earned a news impact score of 0.12 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 47.6465466284389 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Intellia Therapeutics Inc (NTLA) Shares Hold Above the Rising Trendline – Evergreen Caller (evergreencaller.com)
- Intellia Therapeutics, Inc. (NTLA) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- Former GSK exec resigns from Intellia board due to ‘conflict’ – Boston Business Journal (bizjournals.com)
- Investor Update: Company Share Focus for Intellia Therapeutics, Inc. (:NTLA) – Jonesboro Recorder (jonesbororecorder.com)
- Intellia Therapeutics Inc (NTLA) Needle Moving -3.29% – Evergreen Caller (evergreencaller.com)
Shares of Intellia Therapeutics (NASDAQ:NTLA) traded down 3.88% during trading on Thursday, hitting $15.85. 243,244 shares of the stock were exchanged. The company’s market cap is $572.38 million. The firm’s 50-day moving average is $16.53 and its 200 day moving average is $14.41. Intellia Therapeutics has a 1-year low of $10.83 and a 1-year high of $24.90.
Intellia Therapeutics (NASDAQ:NTLA) last posted its earnings results on Thursday, August 3rd. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.03. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The business had revenue of $5.90 million for the quarter, compared to analysts’ expectations of $5.83 million. Intellia Therapeutics’s revenue was up 40.5% compared to the same quarter last year. Equities analysts forecast that Intellia Therapeutics will post ($1.74) earnings per share for the current fiscal year.
Several research analysts have weighed in on NTLA shares. Cann reiterated a “market perform” rating on shares of Intellia Therapeutics in a research note on Monday, July 17th. Credit Suisse Group set a $24.00 price objective on shares of Intellia Therapeutics and gave the company a “buy” rating in a research note on Wednesday, May 3rd. Wedbush reiterated an “outperform” rating and issued a $25.00 price objective on shares of Intellia Therapeutics in a research note on Monday, May 15th. TheStreet raised shares of Intellia Therapeutics from a “d+” rating to a “c-” rating in a research report on Thursday, July 6th. Finally, Oppenheimer Holdings, Inc. started coverage on shares of Intellia Therapeutics in a research report on Tuesday, July 18th. They issued a “market perform” rating for the company. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $24.83.
In other news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the business’s stock in a transaction on Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total value of $2,436,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 12.80% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.